 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H29FN4O2 |
| Molar mass | 400.498 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AB-CHFUPYCA (alsoAB-CHMFUPPYCA)[1] is a compound that was first identified as a component ofsynthetic cannabis products in Japan in 2015.[2][3] The name "AB-CHFUPYCA" is an acronym of its systematic nameN-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(CycloHexylmethyl)-3-(4-FlUorophenyl)-1H-PYrazole-5-CarboxAmide. There are two known regioisomers of AB-CHFUPYCA: 3,5-AB-CHMFUPPYCA (pictured) and 5,3-AB-CHMFUPPYCA.[4] The article[1] refers to both 3,5-AB-CHMFUPPYCA and 5,3-AB-CHMFUPPYCA as AB-CHMFUPPYCA isomers, so AB-CHMFUPPYCA and AB-CHFUPYCA are not names for a unique chemical structure.
AB-CHFUPYCA contains some similar structural elements to other synthetic cannabinoids such as5F-AB-FUPPYCA,JWH-307,JWH-030,JWH-147,AB-PINACA. It may be considered an analog of the traditionalpyrazole cannabinoid receptor 1 antagonistrimonabant. The pharmacological properties of AB-CHFUPYCA have not been studied.
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
